Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Modulation of Host Immunity by the Human Metapneumovirus.

C├ęspedes PF, Palavecino CE, Kalergis AM, Bueno SM.

Clin Microbiol Rev. 2016 Oct;29(4):795-818. doi: 10.1128/CMR.00081-15. Review.

PMID:
27413096
2.

Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.

Mackow N, Amaro-Carambot E, Liang B, Surman S, Lingemann M, Yang L, Collins PL, Munir S.

J Virol. 2015 Oct;89(20):10319-32. doi: 10.1128/JVI.01380-15. Epub 2015 Jul 29.

3.

New Approaches for Immunization and Therapy against Human Metapneumovirus.

Wen SC, Williams JV.

Clin Vaccine Immunol. 2015 Aug;22(8):858-66. doi: 10.1128/CVI.00230-15. Epub 2015 Jun 10. Review.

4.

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Broadbent L, Groves H, Shields MD, Power UF.

Influenza Other Respir Viruses. 2015 Jul;9(4):169-78. doi: 10.1111/irv.12313. Review.

5.

Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.

Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A.

J Virol. 2014 Apr;88(8):4237-50. doi: 10.1128/JVI.03481-13. Epub 2014 Jan 29.

6.

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Mok H, Cheng X, Xu Q, Zengel JR, Parhy B, Zhao J, Wang CK, Jin H.

Open Virol J. 2012;6:12-22. doi: 10.2174/1874357901206010012. Epub 2012 Feb 16.

7.

Targeting RSV with vaccines and small molecule drugs.

Costello HM, Ray WC, Chaiwatpongsakorn S, Peeples ME.

Infect Disord Drug Targets. 2012 Apr;12(2):110-28. Review.

8.

Human Metapneumovirus: lessons learned over the first decade.

Schildgen V, van den Hoogen B, Fouchier R, Tripp RA, Alvarez R, Manoha C, Williams J, Schildgen O.

Clin Microbiol Rev. 2011 Oct;24(4):734-54. doi: 10.1128/CMR.00015-11. Review.

9.

Respiratory syncytial virus vaccine development.

Murata Y.

Clin Lab Med. 2009 Dec;29(4):725-39. doi: 10.1016/j.cll.2009.07.004. Review.

10.

A serum-free Vero production platform for a chimeric virus vaccine candidate.

Yuk IH, Lin GB, Ju H, Sifi I, Lam Y, Cortez A, Liebertz D, Berry JM, Schwartz RM.

Cytotechnology. 2006 Jul;51(3):183-92. doi: 10.1007/s10616-006-9030-7. Epub 2006 Nov 16.

11.

An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.

Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE Jr.

J Virol. 2008 Nov;82(22):11410-8. doi: 10.1128/JVI.01688-08. Epub 2008 Sep 10.

12.

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.

Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, Surman S, Portner A, Slobod KS.

Vaccine. 2007 Dec 17;25(52):8782-93. Epub 2007 Nov 5.

13.

A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE Jr, Williamson RA.

J Virol. 2007 Aug;81(15):8315-24. Epub 2007 May 23.

14.

Nonsegmented negative-strand viruses as vaccine vectors.

Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL.

J Virol. 2006 Nov;80(21):10293-306. Review. No abstract available.

15.

Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.

Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA.

J Virol. 2006 Aug;80(16):7799-806.

16.

Generation of measles virus with a segmented RNA genome.

Takeda M, Nakatsu Y, Ohno S, Seki F, Tahara M, Hashiguchi T, Yanagi Y.

J Virol. 2006 May;80(9):4242-8.

17.

Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.

Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW.

J Virol. 2006 Feb;80(4):2034-44.

18.

A wild goose metapneumovirus containing a large attachment glycoprotein is avirulent but immunoprotective in domestic turkeys.

Bennett RS, LaRue R, Shaw D, Yu Q, Nagaraja KV, Halvorson DA, Njenga MK.

J Virol. 2005 Dec;79(23):14834-42.

20.

Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats.

Hamelin ME, Yim K, Kuhn KH, Cragin RP, Boukhvalova M, Blanco JC, Prince GA, Boivin G.

J Virol. 2005 Jul;79(14):8894-903.

Supplemental Content

Support Center